Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P1101 + Ribavirin in HCV Genotype 1
NCT01587586Phase 2Completed
- Sponsor
- PharmaEssentia
- Start
- Oct 2011
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ropeginterferon alfa-2b in hepatitis C (HCV), sponsored by PharmaEssentia. Started Oct 2011; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01587586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01587586.